Changeflow GovPing Pharma & Drug Safety Compositions and Methods for Treatment and Prev...
Routine Notice Added Final

Compositions and Methods for Treatment and Prevention of Neurological Disorders

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent EP4165025A2 granted to Yumanity Therapeutics, Inc. covering compositions and methods for treating neurological disorders. The patent claims cover specific chemical compounds classified under A61K 31/5377 and A61K 31/519 with applications for neurological conditions including A61P 25/28. The patent is validated in designated European member states including Germany, France, United Kingdom, Italy, and Spain.

What changed

The European Patent Office published patent application EP4165025A2 for Yumanity Therapeutics, Inc., covering compositions and methods for treating and preventing neurological disorders. The patent claims include heterocyclic compounds classified under C07D 239/00 and C07D 239/48 with therapeutic applications for neurodegenerative conditions.

Pharmaceutical companies and biotech firms developing neurological disorder treatments should review this patent for freedom-to-operate considerations. The validated designations cover major European markets including Germany, France, Italy, Spain, and the United Kingdom, creating potential licensing or collaboration opportunities for parties working in related therapeutic areas.

What to do next

  1. Monitor patent portfolio for freedom-to-operate implications
  2. Review compound claims for potential licensing opportunities
  3. Assess therapeutic applications for neurological disease pipeline

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS

Publication EP4165025A2 Kind: A2 Apr 01, 2026

Applicants

Yumanity Therapeutics, Inc.

Inventors

TARDIFF, Daniel, SCANNEVIN, Robert, RHODES, Kenneth

IPC Classifications

A61K 31/5377 20060101AFI20240604BHEP A61K 31/519 20060101ALI20240604BHEP A61P 25/28 20060101ALI20240604BHEP C07D 239/00 20060101ALI20240604BHEP C07D 239/48 20060101ALI20240604BHEP C07D 413/04 20060101ALI20240604BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4165025A2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Pharmaceutical compositions Neurological treatment
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.